The two drugmakers, which have a total market value of almost $240 billion, have not held any formal talks yet. If they were to follow through with this idea, it would be the largest healthcare deal ever. Neither company has publicly commented on the possible deal.
AstraZeneca’s shares grew 11 percent in 2020, as the drugmaker partnered with Oxford University to develop a COVID-19 vaccine. Gilead’s remdesivir drug received emergency approval and is being prescribed as a COVID-19 treatment.
More articles on pharmacy:
Pharmacist salaries across the most common work settings
Remdesivir could make billions for Gilead, analyst says
FDA’s vaccine head quits Operation Warp Speed days after joining
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
